Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) and ImmunityBio (NASDAQ:IBRX – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.
Valuation and Earnings
This table compares Tectonic Therapeutic and ImmunityBio”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tectonic Therapeutic | N/A | N/A | $12.16 million | $0.69 | 57.83 |
| ImmunityBio | $620,000.00 | 6,426.05 | -$583.20 million | ($0.97) | -5.90 |
Tectonic Therapeutic has higher earnings, but lower revenue than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tectonic Therapeutic | 0 | 0 | 4 | 1 | 3.20 |
| ImmunityBio | 0 | 1 | 0 | 1 | 3.00 |
Tectonic Therapeutic currently has a consensus price target of $60.00, suggesting a potential upside of 48.04%. ImmunityBio has a consensus price target of $4.75, suggesting a potential downside of 14.10%. Given Tectonic Therapeutic’s stronger consensus rating and higher probable upside, analysts plainly believe Tectonic Therapeutic is more favorable than ImmunityBio.
Profitability
This table compares Tectonic Therapeutic and ImmunityBio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tectonic Therapeutic | N/A | -41.05% | -37.33% |
| ImmunityBio | -45,691.66% | N/A | -108.04% |
Institutional & Insider Ownership
62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 9.2% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 83.4% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Tectonic Therapeutic has a beta of 2.63, meaning that its share price is 163% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
Summary
Tectonic Therapeutic beats ImmunityBio on 10 of the 13 factors compared between the two stocks.
About Tectonic Therapeutic
Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.
About ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.
